The team behind NeoTargets has long-standing expertise in cancer biology, drug target discovery and drug discovery with a proven ability to bring successful projects to the clinics.

We have established a pioneering oncotarget discovery platform, consisting of an in-silico target assessment tool for systematic identification and prioritisation of targets with optimal characteristics (e.g. “druggability” and selectivity against cancer cells).

Neo targets didn’t emerge in isolation

NeoTargets are closely connected to Karolinska Institutet in Stockholm and that is not a coincidence. Our scientific founders, Julian Walfridsson and Mikael Altun, have spent decades as faculty at Karolinska Institutet in Stockholm, collaborating with researchers, spinouts, and industry partners, bridging basic science and therapeutic development.

Karolinska is one of the most famous universities in Europe, known for top-tier biomedical research (and also where the faculty decides the Nobel Prize in Physiology and Medicine).

Karolinska is a driver of translational innovation, where scientific insights are continuously turned into clinical impact.

In oncology, precision begins with understanding. And few institutions understand cancer biology as good as Karolinska.

Our focus is asset creation and out-licensing/partnering.

NeoTargets has established a platform for the development of safe, new cancer therapeutics from target identification to preclinical drug candidate validation.

• Initially, our proprietary oncotarget platform is applied to generate comprehensive databases of potential drug targets with pre-validated efficacy and safety in different types of cancer.
• Subsequently, drug development projects for selected targets are initiated, now using the platform to screen a diverse range of drug candidates from libraries of traditional small molecule inhibitors, molecular glue degraders, and bifunctional protein degrading molecules such as PROTACs.

For each specific target group or target/candidate combination, the projects aim to generate preclinical proof-of-concept, thereby generating a portfolio of assets.

Assets will be partnered, out-licensed, or sold at various stages of development.

This approach allows us to explore different mechanisms of action and therapeutic strategies  and provide optimal opportunities to partners or licensees to advance the drug candidates further and bring them to market.

Management

Experienced leadership spanning commercialization, cancer biology, translational validation and partnering.